- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00081770
Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)
Comparison of PEG-Intron 1.5µg/kg/wk Plus REBETOL vs PEG-Intron 1µg/kg/wk Plus REBETOL vs PEGASYS 180µg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1
Study Overview
Status
Conditions
Detailed Description
PegIntron Dose will be administered once weekly subcutaneously on the same day of the week:
Screening 2 Weight 40-50 kg Volume to Inject (mL) 0.22; Screening 2 Weight 51-60 kg Volume to Inject (mL) 0.28; Screening 2 Weight 61-75 kg Volume to Inject (mL) 0.33; Screening 2 Weight 76-85 kg Volume to Inject (mL) 0.41; Screening 2 Weight 86-104 kg Volume to Inject (mL) 0.48; Screening 2 Weight 105-125 kg Volume to Inject (mL) 0.58 from two vials
REBETOL Dosage (for Use With PegIntron):
Screening 2 Weight 40-65 kg Daily Dose 800 mg; Screening 2 Weight >65-85 kg Daily Dose 1000 mg; Screening 2 Weight >85-105 kg Daily Dose 1200 mg; Screening 2 Weight >105-125 kg Daily Dose 1400 mg
The PEGASYS dose of 1 mL (180 µg) will be administered once weekly subcutaneously on the same day of the week
COPEGUS Dosage (for Use With PEGASYS):
Screening 2 Weight <75 kg Daily Dose 1000 mg; Screening 2 Weight > or = 75 kg Daily Dose 1200mg
NOTE: Double Blind for PegIntron; Open Label for REBETOL, PEGASYS and COPEGUS
NOTE: REBETOL is the Schering-Plough brand name for ribavirin. COPEGUS is the Hoffman-La Roche brand name for ribavirin.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- Previously untreated adults with chronic hepatitis C (hepatitis C virus ribonucleic acid [HCV RNA] quantitative polymerase chain reaction [qPCR] plasma positive)
- Individuals with HCV genotype 1 (mixed 1a/1b is acceptable)
- Compensated liver disease
- Pretreatment liver biopsy slides available
- Adults aged 18-70
- Individuals weighing 88-275 pounds (40-125 kg)
- Free from substance abuse for past 2 years
- Those suffering from diabetes and/or hypertension must have normal eye exams and retinal photographs (these will be done as part of the study before hepatitis C treatment is given)
- Patients and partners of patients willing to use adequate contraception during the course of the study
Hematology laboratory results of:
- Hemoglobin (HGB) ≥ 12 g/dL for females or ≥ 13g/dL for males
- White Blood Cell Count (WBC) ≥ 3,000/mm^3
- Neutrophils ≥ 1,500/mm^3
- Platelets ≥ 80,000/mm^3
Chemistry laboratory results of:
- Normal Thyroid Stimulating Hormone (TSH), albumin, creatinine, and direct bilirubin
- Antinuclear antibody (ANA) ≤ 1:320
- Fasting Glucose 70-140 mg/dL Note: If glucose levels are between 116-140 mg/dL or an individual has diabetes, glycosylated hemoglobin [HbA1C] must be ≤ 8.5%
EXCLUSION CRITERIA:
- Previous hepatitis C treatment
- Pregnant women or partners of pregnant women
- Patients or partners of patients who intend to become pregnant any time during the 48 weeks
- Women who are breastfeeding
- Individuals with liver disease not caused by hepatitis C
- Individuals infected with the hepatitis B virus and/or human immunodeficiency virus (HIV)
- Patients with a history of liver cancer (hepatocellular carcinoma)
- Known blood disorders such as hemoglobinopathy, coagulopathy, or glucose-6-phosphate dehydrogenase [G6PD] deficiency
- Body organ transplant
- Any known or suspected cancer within the past 5 years
- Individuals who currently use epoetin [EPO], granulocyte colony stimulating factor [G-CSF] and/or granulocyte monocyte colony stimulating factor [GM-CSF]
- Those having a history of or active clinical gout
- Individuals who have chronic pulmonary disease
- Individuals who have a medical condition that would likely require systemic steroids
- Those with a history of central nervous system (CNS trauma) or seizure disorders
- Current or previous use of lithium or antipsychotic drugs
- Individuals who currently have or show signs of moderate to severe depression or history of significant psychiatric disorders
- Patients with clinically significant electrocardiogram (ECG) abnormalities
- Individuals with serious heart problems such as those who have had a heart attack, uncontrolled high blood pressure, or other heart problems
- Patients that weigh > 231-275 pounds (105-125 kg) AND have a body mass index (BMI) > 30 AND have 3 or more of the risk factors below: (a) Strong family history of coronary heart disease (CHD) which includes 2 or more first-degree relatives with CHD or family history of early CHD at age < 55 for male relatives or < 65 for female relatives (b) Individuals with abnormal total cholesterol and/or sub fractions (uncontrolled hypercholesterolemia) (c) Diabetes (d) Hypertension (e) Smoking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PegIntron 1.5 ug/kg/wk plus REBETOL
PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
|
1.5 ug/kg/week subcutaneously (SC) for 48 weeks
Other Names:
1.0 ug/kg/week SC for 48 weeks
Other Names:
weight based dose 800-1400 mg/day orally (PO) for 48 weeks
Other Names:
|
Experimental: PegIntron 1.0 ug/kg/wk plus REBETOL
PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
|
1.5 ug/kg/week subcutaneously (SC) for 48 weeks
Other Names:
1.0 ug/kg/week SC for 48 weeks
Other Names:
weight based dose 800-1400 mg/day orally (PO) for 48 weeks
Other Names:
|
Active Comparator: PEGASYS 180 ug/wk Plus COPEGUS
PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up
|
180 ug/week SC administered for 48 weeks
Other Names:
1000-1200 mg/day PO for 48 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sustained Virologic Response (SVR) Rate
Time Frame: Assessed at the end of a 24-week post-treatment follow-up
|
SVR rate is the percentage of participants with undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at the end of the 24-week post-treatment follow-up.
|
Assessed at the end of a 24-week post-treatment follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in the Log Viral Load at Treatment Week 4
Time Frame: Assessed at Baseline and Treatment Week 4
|
The difference between viral load levels in the blood at the start of the study and Treatment Week 4, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group.
|
Assessed at Baseline and Treatment Week 4
|
Virologic Response Rate at Treatment Week 12
Time Frame: Assessed at Treatment Week 12
|
Percentage of participants with undetectable hepatitis C RNA (HCV-RNA) at Treatment Week 12
|
Assessed at Treatment Week 12
|
Mean Change From Baseline in the Log Viral Load at Treatment Week 2
Time Frame: Assessed at Baseline and Treatment Week 2
|
The difference between viral load levels in the blood at the start of the study and Treatment Week 2, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group.
|
Assessed at Baseline and Treatment Week 2
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22. Erratum In: N Engl J Med. 2009 Sep 3;361(10):1027.
- Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; IDEAL Study Team. Racial differences in hepatitis C treatment eligibility. Hepatology. 2011 Jul;54(1):70-8. doi: 10.1002/hep.24358.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Immunologic Factors
- Interferon-alpha
- Ribavirin
- Peginterferon alfa-2a
- Peginterferon alfa-2b
Other Study ID Numbers
- P03471
- 2552898
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C, Chronic
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis cChina
-
Ascletis Pharmaceuticals Co., Ltd.CompletedChronic Hepatitis cChina
-
Hospices Civils de LyonCompleted
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
Clinical Trials on PegIntron (peginterferon alfa-2b; SCH 54031)
-
Merck Sharp & Dohme LLCCompletedHepatitis C, Chronic
-
Merck Sharp & Dohme LLCCompletedHepatitis D, Chronic | Hepatitis B, Chronic
-
Merck Sharp & Dohme LLCCompletedCirrhosis | Chronic Hepatitis C
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedHepatitis C | Hepatitis C, Chronic
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedHepatitis C | Hepatitis C, Chronic
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted